Physician profile
Karim Nazer
NPI 1174613004
$486.12
in general payments reported to CMS, 2019-2025
15 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $21.05 · 2022: $15.45 · 2023: $37.51 · 2024: $22.55 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $60.69 | 2025 | Mynx Control |
| Merck Sharp & Dohme LLC | $59.15 | 2019-2025 | Zerbaxa |
| Janssen Pharmaceuticals, INC | $54.41 | 2019-2023 | Xarelto |
| Shionogi INC | $53.69 | 2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.94 | 2019 | |
| Insmed, INC. | $28.16 | 2025 | Brinsupri, Arikayce |
| Smith+Nephew, INC. | $26.99 | 2025 | Renasys Touch |
| Astellas Pharma US INC | $22.85 | 2025 | Cresemba |
| Abbvie INC. | $22.69 | 2025 | |
| Mallinckrodt Hospital Products INC. | $22.55 | 2024 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $21.40 | 2019 | |
| Amgen INC. | $18.76 | 2023 | Repatha |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2019 | |
| Alkermes, INC. | $16.63 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Nazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.